In 2006, academic investigators from the NIMH-funded Clinical Antipsychotic Trials of Intervention Effectiveness project (CATIE) entered into scientific collaboration with Eli Lilly and Company to conduct individual GWAS genotyping and jointly analyse the CATIE samples. The collaboration contract required that genotype and phenotype data be made available to the scientific community with intellectual property rights consistent with NIH policies intended to maximize the public benefit resulting from the research. This chapter describes these genetic studies and provides the descriptive data for the cases with schizophrenia and controls. It summarizes the results of the candidate gene studies conducted using genetic samples from CATIE participants. The logistic regression was used to test for association of the 492,900 SNPs in the GWAS data set with case/control status. The principal finding of the CATIE GWAS was that no single nucleotide polymorphism (SNP) or multi-marker combination of SNPs achieved genomewide significance.